Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026)
Precision Biosciences (DTIL) reported Return on Capital Employed of 27.66% for Q1 2026, up 970.0% year-over-year from 2.59% in Q1 2025, and up 38.98% quarter-over-quarter from 45.33% in Q4 2025.
Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 8 years of Return on Capital Employed data on file, last reported at 27.66% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 27.66%, up 970.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 27.66% (up 970.0% YoY), and the FY2025 annual result was 38.21%, down 1855.0% from the prior year.
- Return on Capital Employed climbed to 27.66% in Q1 2026 per DTIL's latest filing, from 45.33% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 5.13% in Q2 2024 and troughed at 103.8% in Q3 2025.
- A 5-year average of 39.86% and a median of 37.36% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed soared 4229 bps in 2022, then slumped 9282 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 42.85% in 2022, then climbed by 9 bps to 39.02% in 2023, then surged by 48 bps to 20.15% in 2024, then plunged by 125 bps to 45.33% in 2025, then jumped by 39 bps to 27.66% in 2026.
- Business Quant data shows DTIL's Return on Capital Employed at 27.66% in Q1 2026, 45.33% in Q4 2025, and 103.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -27.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.66% |
| Dec 31, 2025 | -45.33% |
| Sep 30, 2025 | -103.80% |
| Jun 30, 2025 | -87.40% |
| Mar 31, 2025 | -37.36% |
| Dec 31, 2024 | -20.15% |
| Sep 30, 2024 | -10.98% |
| Jun 30, 2024 | -5.13% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -39.02% |
| Sep 30, 2023 | -33.46% |
| Jun 30, 2023 | -31.65% |
| Mar 31, 2023 | -39.94% |
| Dec 31, 2022 | -42.85% |
| Sep 30, 2022 | -45.81% |
| Jun 30, 2022 | -53.50% |
| Mar 31, 2022 | -28.67% |
| Dec 31, 2021 | -21.47% |
| Sep 30, 2021 | -16.72% |
| Jun 30, 2021 | -22.21% |